Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Population Health Research Institute · Hamilton Health Sciences · +44 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
475
total citations
- FWCI
- 42.24
- Percentile
- 100%
- References
- 38
Citations per year
Authors
50- PMPaul MoayyediCorresponding
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- JWJohn W. Eikelboom
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- JBJackie Bosch
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- SJStuart J. Connolly
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- LDLeanne Dyal
Population Health Research Institute, Hamilton Health Sciences, McMaster University
Topics & keywords
Topics
Keywords
- Rivaroxaban
- Aspirin
- Medicine
- Randomized controlled trial
- Internal medicine
- Pharmacology
- Warfarin
- Atrial fibrillation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.